This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Haywood, L. J. Search for Related Content PubMed PubMed Citation Articles by Haywood, L. J.

QUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS

Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

L. Julian Haywood, MD^_*, Charles E. Ford, PhD^,_*, Richard S. Crow, MD, Barry R. Davis, MD, PhD, Barry M. Massie, MD, Paula T. Einhorn, MD^||, Angela Williard, RN, BSN^¶ for the ALLHAT Collaborative Research Group

^_* Los Angeles County/University of Southern California Medical Center, Los Angeles, California
University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas
University of Minnesota, Minneapolis, Minnesota
San Francisco Veterans Affairs Medical Center, San Francisco, California
^|| Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland
^¶ Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana

Manuscript received December 22, 2008; revised manuscript received August 7, 2009, accepted August 18, 2009.

^_* Reprint requests and correspondence: Dr. Charles E. Ford, The University of Texas School of Public Health, 1200 Herman Pressler Drive, E-827, Houston, Texas 77030 (Email: charles.e.ford{at}uth.tmc.edu).

Objectives: The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CHD) or other cardiovascular events. This subanalysis examines baseline prevalence and in-trial incidence of new-onset atrial fibrillation (AF) or atrial flutter (AFL) and their influence on clinical outcomes.

Background: Limited information is available on whether atrial fibrillation incidence is affected differentially by different classes of antihypertensive medications or treatment with statins.

Methods: AF/AFL was identified from baseline and follow-up electrocardiograms performed biannually. Analyses were performed to identify characteristics associated with baseline AF/AFL and its subsequent incidence.

Results: AF/AFL was present at baseline in 423 participants (1.1%), more frequent in men (odds ratio: 1.72; 95% confidence interval [CI]: 1.37 to 2.17) and nonblacks (odds ratio: 2.09; 95% CI: 1.58 to 2.75). Its prevalence increased with age (p < 0.001) and was associated with CHD, cardiovascular disease, obesity, and high-density lipoprotein cholesterol <35 mg/dl. New-onset AF/AFL was associated with the same baseline risk factors plus electrocardiogram left ventricular hypertrophy. It occurred in 641 participants (2.0%) and, excluding doxazosin, did not differ by antihypertensive treatment group or, in a subset of participants, by pravastatin versus usual care. Baseline AF/AFL was associated with increased mortality (hazard ratio [HR]: 2.82; 95% CI: 2.36 to 3.37; p < 0.001), stroke (HR: 3.63; 95% CI: 2.72 to 4.86; p < 0.001), heart failure (HR: 3.17; 95% CI: 2.38 to 4.25; p < 0.001), and fatal CHD or nonfatal myocardial infarction (HR: 1.64; 95% CI: 1.22 to 2.21; p < 0.01). There was a nearly 2.5-fold increase in mortality risk when AF/AFL was present at baseline or developed during the trial (HR: 2.42; 95% CI: 2.11 to 2.77; p < 0.001).

Conclusions: In this high-risk hypertensive population, pre-existing and new-onset AF/AFL were associated with increased mortality. Excluding doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus usual care did not affect AF/AFL incidence. (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]; NCT00000542)

Key Words: hypertension • atrial fibrillation • clinical trial • chlorthalidone • amlodipine • lisinopril • doxazosin • pravastatin

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   AF = atrial fibrillation   AFL = atrial flutter   ARB = angiotensin receptor blocker   ASCVD = atherosclerotic cardiovascular disease   BMI = body mass index   BP = blood pressure   CHD = coronary heart disease   CI = confidence interval   CVD = cardiovascular disease   ECG = electrocardiogram   eGFR = estimated glomerular filtration rate   HR = hazard ratio   LVH = left ventricular hypertrophy   OR = odds ratio   PH = proportional hazards

This article has been cited by other articles:

				P. Verdecchia, G. Mazzotta, F. Angeli, and G. Reboldi Above Which Blood Pressure Level Does the Risk of Atrial Fibrillation Increase? Hypertension, February 1, 2012; 59(2): 184 - 185. [Full Text] [PDF]

				A. Alonso, F. L. Lopez, K. Matsushita, L. R. Loehr, S. K. Agarwal, L. Y. Chen, E. Z. Soliman, B. C. Astor, and J. Coresh Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study Circulation, June 28, 2011; 123(25): 2946 - 2953. [Abstract] [Full Text] [PDF]

				P. W. Macfarlane, H. Murray, N. Sattar, D. J. Stott, I. Ford, B. Buckley, J. W. Jukema, R. G. J. Westendorp, and J. Shepherd The incidence and risk factors for new onset atrial fibrillation in the PROSPER study Europace, May 1, 2011; 13(5): 634 - 639. [Abstract] [Full Text] [PDF]

				T. Yamashita, H. Inoue, K. Okumura, I. Kodama, Y. Aizawa, H. Atarashi, T. Ohe, H. Ohtsu, T. Kato, S. Kamakura, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study) Europace, April 1, 2011; 13(4): 473 - 479. [Abstract] [Full Text] [PDF]

				A. Goette The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation Europace, April 1, 2011; 13(4): 451 - 452. [Full Text] [PDF]

				K. Rahimi, J. Emberson, P. McGale, W. Majoni, A. Merhi, F. W. Asselbergs, V. Krane, P. W. Macfarlane, and PWM is acting on behalf of the PROSPER Executive Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials BMJ, March 16, 2011; 342(mar16_2): d1250 - d1250. [Abstract] [Full Text] [PDF]

				I. Savelieva, N. Kakouros, A. Kourliouros, and A. J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention Europace, March 1, 2011; 13(3): 308 - 328. [Abstract] [Full Text] [PDF]

				A. J. S. Webb and P. M. Rothwell Blood Pressure Variability and Risk of New-Onset Atrial Fibrillation: A Systematic Review of Randomized Trials of Antihypertensive Drugs Stroke, September 1, 2010; 41(9): 2091 - 2093. [Abstract] [Full Text] [PDF]